[Effect of rG-CSF on the morphology and function of neutrophils in ovarian cancer chemotherapy].
The combined use of rG-CSF in ovarian cancer chemotherapy prevents a decrease in the number of neutrophils and promotes their recovery. rG-CSF also protects against infections, enhancing chemotherapeutic effectiveness. It is reported that neutrophils produced by rG-CSF not only increase in number but also in function. Some clinicians, however, doubt whether neutrophils mobilized or produced by rG-CSF have sufficient ability to function practically in clinical cases. We therefore examined, by means of flow cytometry, the neutrophils' phagocytosis and bactericidal ability and we found both normal. No morphological abnormalities were seen in these neutrophils. In our observations, moreover, no effect was exerted on the leukocyte-membrane antigen. It was concluded that (a) rG-CSF was very effective in protecting against the diminution of neutrophils by chemotherapy and (b) in promoting their recovery, and (c) also the function, morphology and leukocyte-membrane antigen of these neutrophils were normal.
Hoshino
T
T
Department of Obstetrics and Gynecology, Tokyo Medical College.
Suzuki
Y
Y
Adachi
T
T
Okabe
K
K
Takayama
M
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003536:Cystadenocarcinoma / Q000097:blood / Q000188:drug therapy*; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005434:Flow Cytometry; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007958:Leukocyte Count; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects* / Q000502:physiology; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy*; D010587:Phagocytosis / Q000187:drug effects; D010752:Phosphoramide Mustards / Q000008:administration & dosage; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use
D010752:Phosphoramide Mustards; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D004317:Doxorubicin; D002945:Cisplatin